canertinib dihydrochloride has been researched along with canertinib in 1 studies
Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) | Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) |
---|---|---|---|---|---|
31 | 13 | 6 | 124 | 9 | 65 |
Protein | Taxonomy | canertinib dihydrochloride (IC50) | canertinib (IC50) |
---|---|---|---|
Epidermal growth factor receptor | Homo sapiens (human) | 0.0068 | |
Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0757 | |
Tyrosine-protein kinase Blk | Homo sapiens (human) | 0.0395 | |
Cytoplasmic tyrosine-protein kinase BMX | Homo sapiens (human) | 0.324 | |
Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 2.94 | |
Dipeptidyl peptidase 1 | Homo sapiens (human) | 2.7 | |
Tyrosine-protein kinase BTK | Homo sapiens (human) | 0.185 | |
Tyrosine-protein kinase ITK/TSK | Homo sapiens (human) | 5.65 | |
Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.0103 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bridges, AJ; Denny, WA; Elliott, WL; Fry, DW; McNamara, DJ; Nelson, JM; Roberts, BJ; Sherwood, V; Showalter, HD; Smaill, JB; Vincent, PW; Zhou, H | 1 |
1 other study(ies) available for canertinib dihydrochloride and canertinib
Article | Year |
---|---|
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Inhibitory Concentration 50; Mice; Phosphorylation; Pyrimidines; Quinazolines; Solubility; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |